A phase I, open-label, prospective, randomized, drug-drug interaction study of Omeprazole with Ombitasvir/paritaprevir/ritonavir with or without Dasabuvir in healthy subjects
Latest Information Update: 11 Aug 2016
Price :
$35 *
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Omeprazole (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 11 Aug 2016 New trial record.
- 01 Jul 2016 Results published in the Clinical Pharmacology in Drug Development